Pharmaceutical Intermediate Lab Supply Powder Peptide Aod9604 for Bodybuilding
实验室供应Aod9604肌肉建设高品质（2毫克/瓶）
| 型号。 | API |
| 定制 | 定制 |
| 适合 | 老人，成人 |
| 纯度 | >98% |
| 应用 | 制药 |
| 出现 | 冻干粉 |
| 功能 | 肌肉构建 |
| 商标 | 过滤 |
| 规范 | iu，mg，g，kg |
| HS编码 | 2801100000 |
| 粉末 | 是 |
| 证明 | gmp，hse，iso 9001，usp，bp |
| 州 | 固体 |
| 产品名称 | AOD9604 |
| 颜色 | 白色 |
| CAS | 221231-10-3 |
| MOQ | 10vial |
| 运输包装 | 塑料管 |
| 起源 | 上海 |
药物中间体实验室供应用于健美的粉末肽Aod9604 WODT说，AOD-9604是人类生长激素的修饰片段，最初由澳大利亚莫纳什大学的吴教授于1990年代开发。
虽然AOD9604未经澳大利亚TGA批准，但可由医生处方合法获得，并由复合药房（2）分发。许多实验物质都是如此，但它对AOD9604的声誉有很大的帮助，给人的印象是，像医疗行业发布的其他药物一样，它是一种有效和高质量的产品。这些原因，当一起考虑时，给人一个强大的印象，肽是非常有效的 - 他们不会禁止他们没有理由，他们会吗？
代谢药物已经报道，最近的体外试验表明，AOD9604可能刺激骨细胞和肌肉和软骨细胞的生长。这些结果尚未在动物或人类中复制（4）。有许多推测，代谢公司正在为埃森登足球俱乐部的球员提供AOD9604，作为秘密临床试验的一部分，但该公司已经公然否认了这一说法，声称自2007年以来没有进行任何人体试验（2）。 AOD9604已经被科学证明是安全和无副作用的（2），显然很难在血液中检测到。
2001年至2007年间，代谢药物将注意力转移到人类研究方面，对925人进行了6项临床试验。其中没有一项试验表明AOD9604引起体重减轻或身体组成变化（3）。 2007年，拥有卡尔萨达代谢公司的公司向其股东报告AOD9604没有显示任何承诺，并被放弃为减肥药物（2,3）。尽管啮齿类动物研究显示口服给药途径有效，但是通过口服给药对肽药物的吸收效率低下，这种失败归咎于试验。在这一点上，Metabolic已经斥资5000万美元，开发和试用了AOD9604。
2010年，该公司听说健美运动员正在从中国进口专利保护肽的淘汰版，并开始向其他公司许可制造权，试图竞争，因为这被确定为更好的过程而不是企图起诉中国公司的专利侵权（7,8）。与Phosphagenics公司（4）合作，他们绝望地收回了这笔投资，他们投入了少量额外的技术来开发一种允许肽被皮肤吸收的技术。然后该肽被许可用于BodyShaper，一种抗脂肪膏。随后，磷酸盐化剂从BodyShaper中下降了AOD9604，引用过多的费用和无效（3）。
当AFL多肽丑闻受到打击时，Calzada被迫澄清了关于AOD9604的事实，并针对潜在投资者提出了一个巧妙的措辞，专注于AOD9604在大规模临床试验中被证明是安全的（忽视提及并说明了AOD9604在刺激骨骼生长方面的成功，以及在体外试验中软骨和肌肉细胞修复（2,4）。黑色市场用于肌肉修复和治疗肥胖的这种肽也在释放中提及，通过媒体报道，这个丑闻很明显，Calzada从轮廓增强中获得了牵引力（8）。
如果科学界对AOD9604有一个明确的说法，那就是它是安全的，没有副作用。 Calzada在尝试将肽作为抗肥胖和抗关节炎药物后，成功地将该肽称为“通常被认为是安全的”，这使得它在美国被用作食品添加剂是合法的。 Calzada似乎并不表示他们的产品具有药物性质，现在正试图通过AOD9604（2,4）的反补贴和“营养品”市场进入美国。有趣的是，该化合物仅被批准用于每天高达1mg的水平（2），而试验中使用的剂量通常在500ug / kg（5,6）左右，这意味着100kg的人接受了50mg的每天肽。没有科学背后的肽或剂量，而Calzada本身以前曾说过AOD9604是没有口服有效的（2）口服有效（2）。
新闻报道和口碑在AOD9604周围产生了颇多的炒作。尽管它在黑市上受欢迎，但是没有研究在高剂量下注射该肽的安全性和效果。有趣的是，尽管它是一个获得专利的产品，但目前Calcalada并不关心AOD9604的黑市生产。 Calzada缺乏资金合法地通过临床试验提高这种肽的声誉，而且有可能再次证明AOD9604没有效果。该肽目前享有良好的信誉可能会在美国作为食品添加剂的市场营销提供强有力的杠杆作用。
WODT说，AOD-9604是人类生长激素的修饰片段，最初由澳大利亚莫纳什大学的吴教授于1990年代开发。
AOD-9604（添加到N-末端的酪氨酸残基177-191）肯定促进大鼠和小鼠的脂肪减少。据了解，它只通过增加β-3受体的数量和活性才起作用。
在这些物种中，β-3受体与总代谢有很高的相关性。在人类中，相关性并不多。
AOD9604 - 这是什么？
AOD9604是一种肽（一条氨基酸链），由一家名为Metabolic Pharmaceuticals的公司在20世纪90年代后期开发并获得专利。 AOD代表“抗肥胖药”。该肽具有模拟人生长激素（该激素被认为是燃烧脂肪的区域）的脂肪分解区域的氨基酸序列，并且已作为减肥补充剂被多种促进，作为对肌肉和软骨修复的辅助，以及其制造商对骨关节炎的治疗。也称为促脂素和Tyr-hGH片段，并且这些天通常可用作透皮霜或可注射的。AOD9604 - 为什么人们使用它？
AOD9604被各种制造商大量推广，作为能够燃烧脂肪并协助肌肉和软骨修复的物质。事实上，这种产品源于并声称模仿强大的合成代谢禁用物质的效果，为许多潜在用户提供了心理上的激励，正如AFL'多肽在2013年初的丑闻和随后的报告澳大利亚犯罪委员会（1）。虽然AOD9604未经澳大利亚TGA批准，但可由医生处方合法获得，并由复合药房（2）分发。许多实验物质都是如此，但它对AOD9604的声誉有很大的帮助，给人的印象是，像医疗行业发布的其他药物一样，它是一种有效和高质量的产品。这些原因，当一起考虑时，给人一个强大的印象，肽是非常有效的 - 他们不会禁止他们没有理由，他们会吗？
代谢药物已经报道，最近的体外试验表明，AOD9604可能刺激骨细胞和肌肉和软骨细胞的生长。这些结果尚未在动物或人类中复制（4）。有许多推测，代谢公司正在为埃森登足球俱乐部的球员提供AOD9604，作为秘密临床试验的一部分，但该公司已经公然否认了这一说法，声称自2007年以来没有进行任何人体试验（2）。 AOD9604已经被科学证明是安全和无副作用的（2），显然很难在血液中检测到。
AOD9604 - 负面
最大的消极，这是一个大的，是AOD9604经历了非常严格的科学测试，已被发现对人类没有影响（3）。当AOD9604首次开发时，作为减肥治疗显示出显着的前景。补充有肽的肥胖小鼠的特殊菌株显示重量减轻，脂肪氧化增加，和升高的血浆甘油，这是脂肪分解或脂肪燃烧的指标（5）。随后在肥胖小鼠和大鼠中的研究试图表明该肽以与人生长激素相同的方式起作用燃烧脂肪，但发现不是这种情况，这意味着该肽类似于hGH的事实是无意义的。科学家无法确定这种肽在小鼠中的作用（6）。2001年至2007年间，代谢药物将注意力转移到人类研究方面，对925人进行了6项临床试验。其中没有一项试验表明AOD9604引起体重减轻或身体组成变化（3）。 2007年，拥有卡尔萨达代谢公司的公司向其股东报告AOD9604没有显示任何承诺，并被放弃为减肥药物（2,3）。尽管啮齿类动物研究显示口服给药途径有效，但是通过口服给药对肽药物的吸收效率低下，这种失败归咎于试验。在这一点上，Metabolic已经斥资5000万美元，开发和试用了AOD9604。
2010年，该公司听说健美运动员正在从中国进口专利保护肽的淘汰版，并开始向其他公司许可制造权，试图竞争，因为这被确定为更好的过程而不是企图起诉中国公司的专利侵权（7,8）。与Phosphagenics公司（4）合作，他们绝望地收回了这笔投资，他们投入了少量额外的技术来开发一种允许肽被皮肤吸收的技术。然后该肽被许可用于BodyShaper，一种抗脂肪膏。随后，磷酸盐化剂从BodyShaper中下降了AOD9604，引用过多的费用和无效（3）。
当AFL多肽丑闻受到打击时，Calzada被迫澄清了关于AOD9604的事实，并针对潜在投资者提出了一个巧妙的措辞，专注于AOD9604在大规模临床试验中被证明是安全的（忽视提及并说明了AOD9604在刺激骨骼生长方面的成功，以及在体外试验中软骨和肌肉细胞修复（2,4）。黑色市场用于肌肉修复和治疗肥胖的这种肽也在释放中提及，通过媒体报道，这个丑闻很明显，Calzada从轮廓增强中获得了牵引力（8）。
如果科学界对AOD9604有一个明确的说法，那就是它是安全的，没有副作用。 Calzada在尝试将肽作为抗肥胖和抗关节炎药物后，成功地将该肽称为“通常被认为是安全的”，这使得它在美国被用作食品添加剂是合法的。 Calzada似乎并不表示他们的产品具有药物性质，现在正试图通过AOD9604（2,4）的反补贴和“营养品”市场进入美国。有趣的是，该化合物仅被批准用于每天高达1mg的水平（2），而试验中使用的剂量通常在500ug / kg（5,6）左右，这意味着100kg的人接受了50mg的每天肽。没有科学背后的肽或剂量，而Calzada本身以前曾说过AOD9604是没有口服有效的（2）口服有效（2）。
新闻报道和口碑在AOD9604周围产生了颇多的炒作。尽管它在黑市上受欢迎，但是没有研究在高剂量下注射该肽的安全性和效果。有趣的是，尽管它是一个获得专利的产品，但目前Calcalada并不关心AOD9604的黑市生产。 Calzada缺乏资金合法地通过临床试验提高这种肽的声誉，而且有可能再次证明AOD9604没有效果。该肽目前享有良好的信誉可能会在美国作为食品添加剂的市场营销提供强有力的杠杆作用。
AOD9604法律状态
AOD9604在澳大利亚购买AOD9604是非法的，但TGA尚未获得批准，这意味着不得以任何药物或性能提升的方式出售。除了FDA以前提及的“一般被认为是安全”的指定外，世界上任何药物管理机构都没有得到批准。 AOD9604目前由世界反兴奋剂机构（WADA）列为未经批准的物质，这意味着运动员在竞赛中不合法使用。世界无线电通信局的政策是禁止所有涉及性能提升的物质，即使没有临床证明（1,2）.roof（1,2）。 自我介绍
这是Grace从 郑州过滤生物科技有限公司 我们拥有专业实验室，为所有客户长期合作确认质量和服务。
我们公司为 制药原料制造商专业研发; DD the 新药 和 生产普通医学:
1：健美肽
2：化妆品肽
3：类固醇
4：氨基酸
5：定制服务
由于质量高，服务好，已出口30多个国家。
真诚希望有机会与您合作。
这是Grace从 郑州过滤生物科技有限公司 我们拥有专业实验室，为所有客户长期合作确认质量和服务。
我们公司为 制药原料制造商专业研发; DD the 新药 和 生产普通医学:
1：健美肽
2：化妆品肽
3：类固醇
4：氨基酸
5：定制服务
由于质量高，服务好，已出口30多个国家。
真诚希望有机会与您合作。
| Model NO. | API |
| Customized | Customized |
| Suitable for | Elderly, Adult |
| Purity | >98% |
| Application | Pharmaceutical |
| Appearance | Lyophilized Powder |
| Function | Muscle Build |
| Trademark | Filter |
| Specification | iu, mg, g, kg |
| HS Code | 2801100000 |
| Powder | Yes |
| Certification | GMP, HSE, ISO 9001, USP, BP |
| State | Solid |
| Product Name | Aod9604 |
| Color | White |
| CAS | 221231-10-3 |
| MOQ | 10vial |
| Transport Package | Plastic Tube |
| Origin | Shanghai |
Pharmaceutical Intermediate Lab Supply Powder Peptide Aod9604 for Bodybuilding AOD-9604 is a modified fragment of human growth hormone that was originally developed by Professor Frank Ng at Monash University in Australia in the 1990s, says Wittert.
Whilst AOD9604 is not approved by the Australian TGA, it can be legally obtained on a doctor's prescription and dispensed by a compounding pharmacy (2). This is true of many experimental substances, but it does big favours for the reputation of AOD9604, giving the impression that, like other drugs issued by the medical profession, it is an efficacious and high quality product. These reasons, when considered together, give a powerful impression that peptides are highly effective - they wouldn't ban them for no reason, would they?
Metabolic Pharmaceuticals have reported that recent in vitro trials have shown that AOD9604 may stimulate the growth of bone cells, and muscle and cartilage cells. These results have not yet been reproduced in animals or humans (4). There was a lot of speculation that Metabolic was providing AOD9604 to players at the Essendon Football Club as part of a secret clinical trial, but the company has flatly denied this claim, claiming it has not run any human trials since 2007 (2). AOD9604 has been scientifically proven safe and side-effect free (2), and is apparently very difficult to detect in the blood.
Metabolic turned their attention to human studies and performed six clinical trials on 925 people between 2001 and 2007. Not one of these trials showed that AOD9604 caused any weight loss or changes in body composition (3). In 2007, the company that owns Metabolic, Calzada, reported to their shareholders that AOD9604 showed no promise, and was being abandoned as a weight loss drug (2,3). The failure was blamed on inefficient absorption of the peptide drug through oral administration, as was used in the trials, even though rodent studies had shown the oral delivery route to be effective. At this point, Metabolic had sunk a massive $50 million into development and trials of AOD9604.
In 2010, the company heard word that bodybuilders were importing knock-off versions of the patent-protected peptide from China, and started licensing the manufacturing rights out to other companies in an attempt to compete, as this was determined to be a better course of action than attempting to sue the Chinese company for patent breach (7, 8). Desperate to recoup this investment, they invested a small additional amount into developing a technology that allowed the peptide to be absorbed through the skin, in collaboration with a company called Phosphagenics (4). The peptide was then licensed for use in BodyShaper, an anti-cellulite cream. Phosphagenics later dropped AOD9604 from BodyShaper, citing excessive expense and ineffectiveness (3).
When the AFL Peptides scandal hit, Calzada was forced to clarify the facts about AOD9604, and put out a cleverly worded press statement aimed at potential investors, concentrating on the fact that AOD9604 had been proven safe in large scale clinical trials (neglecting to mention a lack of effectiveness) and spoke of the success of AOD9604 on stimulating bone growth, and on cartilage and muscle cell repair in in-vitro trials (2,4). The black market uses for this peptide in muscle repair and treatment of obesity were also mentioned in the release, and it is clear through media reports on this scandal that Calzada gained traction from the profile boost (8).
If there's one thing that science has definitively said about AOD9604, it is that it is safe and has no side effects. Calzada, after trying the peptide out as an anti-obesity and anti-arthritic, has succeeded in having the peptide declared 'Generally regarded as safe' by the FDA, which makes it legal to use as a food additive in America. Calzada, seemingly under no pretense that their product has pharmaceutical properties, is now trying to break into the US over the counter supplement and 'Nutraceutical' market with AOD9604 (2,4). Interestingly, the compound has only been approved for use in levels of up to 1mg per day (2), whereas the doses used in trials generally hovered around 500ug/kg (5,6), which means a 100kg person was receiving 50mg of the peptide daily. There is no science behind the peptide, or the dosage, and Calzada themselves have previously said AOD9604 is not effective orally (2).effective orally (2).
Press coverage and word of mouth has generated quite a bit of hype around AOD9604. Despite its popularity on the black market, there is no research into the safety and effect of injecting this peptide at high doses. Intriguingly, it is not currently in Calzada's interest to fight the black market production of AOD9604, even though it is a patented product. Calzada lack the funds to legitimately boost the reputation of this peptide through clinical trials, and there is a strong chance these would once again prove that AOD9604 has no effect. The good reputation this peptide currently enjoys is likely to provide strong leverage to its marketing as a food supplement in the United States.
AOD-9604 is a modified fragment of human growth hormone that was originally developed by Professor Frank Ng at Monash University in Australia in the 1990s, says Wittert.
AOD-9604 (residues 177-191 with a tyrosine added to the N-terminus) certainly promotes fat loss in rats and mice. So far as is known, it works in them only by increasing the number and activity of beta-3 receptors.
In these species, beta-3 receptors have very high relevance to overall metabolism. In humans, the relevance is not much.
AOD9604 - What is it?
AOD9604 is a peptide (a chain of amino acids) which was developed and patented by a company called Metabolic Pharmaceuticals in Australia in the late 1990s. AOD stands for 'Anti Obesity Drug'. This peptide has an amino acid sequence that mimics the lipolytic region of human growth hormone (the region of this hormone thought to be responsible for burning fat) and it has been promoted variously as a weight loss supplement, as an aid to muscle and cartilage repair, and a treatment for osteoarthritis by its manufacturers. It is also known as lipotropin and Tyr-hGH fragment, and is generally available these days as a transdermal cream or an injectable.injectable.AOD9604 - Why do people use it?
AOD9604 is promoted heavily by various manufacturers as a substance that is able to burn fat and assist in the repair of muscle and cartilage. The fact that this product derives from, and claims to mimic the effects of a powerfully anabolic banned substance provides a psychological incentive to many potential users, as does the attention drawn by the AFL 'peptides' scandal of early 2013 and the subsequent report by the Australian Crime Commission (1).ission (1).Whilst AOD9604 is not approved by the Australian TGA, it can be legally obtained on a doctor's prescription and dispensed by a compounding pharmacy (2). This is true of many experimental substances, but it does big favours for the reputation of AOD9604, giving the impression that, like other drugs issued by the medical profession, it is an efficacious and high quality product. These reasons, when considered together, give a powerful impression that peptides are highly effective - they wouldn't ban them for no reason, would they?
Metabolic Pharmaceuticals have reported that recent in vitro trials have shown that AOD9604 may stimulate the growth of bone cells, and muscle and cartilage cells. These results have not yet been reproduced in animals or humans (4). There was a lot of speculation that Metabolic was providing AOD9604 to players at the Essendon Football Club as part of a secret clinical trial, but the company has flatly denied this claim, claiming it has not run any human trials since 2007 (2). AOD9604 has been scientifically proven safe and side-effect free (2), and is apparently very difficult to detect in the blood.
AOD9604 - The Negatives
The biggest negative, and this is a big one, is that AOD9604 has undergone very rigorous scientific testing, and has been found to have no effect in humans (3). When AOD9604 was first developed, it showed significant promise as a weight loss treatment. A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis, or fat burning (5). Subsequent studies in obese mice and rats attempted to show that the peptide works to burn fat in the same way as human growth hormone, but found that this was not the case, meaning that the fact this peptide resembled hGH was meaningless. Scientists were unable to determine how this peptide was working in mice (6).Metabolic turned their attention to human studies and performed six clinical trials on 925 people between 2001 and 2007. Not one of these trials showed that AOD9604 caused any weight loss or changes in body composition (3). In 2007, the company that owns Metabolic, Calzada, reported to their shareholders that AOD9604 showed no promise, and was being abandoned as a weight loss drug (2,3). The failure was blamed on inefficient absorption of the peptide drug through oral administration, as was used in the trials, even though rodent studies had shown the oral delivery route to be effective. At this point, Metabolic had sunk a massive $50 million into development and trials of AOD9604.
In 2010, the company heard word that bodybuilders were importing knock-off versions of the patent-protected peptide from China, and started licensing the manufacturing rights out to other companies in an attempt to compete, as this was determined to be a better course of action than attempting to sue the Chinese company for patent breach (7, 8). Desperate to recoup this investment, they invested a small additional amount into developing a technology that allowed the peptide to be absorbed through the skin, in collaboration with a company called Phosphagenics (4). The peptide was then licensed for use in BodyShaper, an anti-cellulite cream. Phosphagenics later dropped AOD9604 from BodyShaper, citing excessive expense and ineffectiveness (3).
When the AFL Peptides scandal hit, Calzada was forced to clarify the facts about AOD9604, and put out a cleverly worded press statement aimed at potential investors, concentrating on the fact that AOD9604 had been proven safe in large scale clinical trials (neglecting to mention a lack of effectiveness) and spoke of the success of AOD9604 on stimulating bone growth, and on cartilage and muscle cell repair in in-vitro trials (2,4). The black market uses for this peptide in muscle repair and treatment of obesity were also mentioned in the release, and it is clear through media reports on this scandal that Calzada gained traction from the profile boost (8).
If there's one thing that science has definitively said about AOD9604, it is that it is safe and has no side effects. Calzada, after trying the peptide out as an anti-obesity and anti-arthritic, has succeeded in having the peptide declared 'Generally regarded as safe' by the FDA, which makes it legal to use as a food additive in America. Calzada, seemingly under no pretense that their product has pharmaceutical properties, is now trying to break into the US over the counter supplement and 'Nutraceutical' market with AOD9604 (2,4). Interestingly, the compound has only been approved for use in levels of up to 1mg per day (2), whereas the doses used in trials generally hovered around 500ug/kg (5,6), which means a 100kg person was receiving 50mg of the peptide daily. There is no science behind the peptide, or the dosage, and Calzada themselves have previously said AOD9604 is not effective orally (2).effective orally (2).
Press coverage and word of mouth has generated quite a bit of hype around AOD9604. Despite its popularity on the black market, there is no research into the safety and effect of injecting this peptide at high doses. Intriguingly, it is not currently in Calzada's interest to fight the black market production of AOD9604, even though it is a patented product. Calzada lack the funds to legitimately boost the reputation of this peptide through clinical trials, and there is a strong chance these would once again prove that AOD9604 has no effect. The good reputation this peptide currently enjoys is likely to provide strong leverage to its marketing as a food supplement in the United States.
AOD9604 Legal Status
Whilst not illegal to buy AOD9604 in Australia, AOD9604 does not have approval by the TGA, which means it is not allowed to be sold on the basis of it having any pharmaceutical or performance enhancing benefits. It has not been approved by any pharmaceutical authority worldwide, except for the previously mentioned 'Generally Regarded As Safe' designation by the FDA. AOD9604 is currently classed by the World Anti Doping Agency (WADA) as a non-approved substance, which means it is not legal for use by athletes in competition. WADA policy is to ban all substances that are suspected of being performance-enhancing, even in the absence of clinical proof (1,2).roof (1,2). Self-introduction
This is Grace from Zhengzhou Filter Biotechnology Co.,Ltd. we have Professional Lab to confirm the Quality and Serive for all clients in long-term run cooperation.
Our Company as a Pharmaceutical Raw Material Manufacturerspecialize in R&D the;D theD the New Drugs and Producing the Generic Medicine:
1:Bodybuilding Peptides
2:Cosmetic Peptides
3:Steroids
4:Amino Acid
5:Custom-made Service
Due to of the high quality and good service, They have been exported more than 30 countries.
Sincerely hope to have a chance to cooperate with you.
This is Grace from Zhengzhou Filter Biotechnology Co.,Ltd. we have Professional Lab to confirm the Quality and Serive for all clients in long-term run cooperation.
Our Company as a Pharmaceutical Raw Material Manufacturerspecialize in R&D the;D theD the New Drugs and Producing the Generic Medicine:
1:Bodybuilding Peptides
2:Cosmetic Peptides
3:Steroids
4:Amino Acid
5:Custom-made Service
Due to of the high quality and good service, They have been exported more than 30 countries.
Sincerely hope to have a chance to cooperate with you.
